Sanofi India Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Sanofi India Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $9.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sanofi India Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $9.0M Trade | TransData Nexus

Sanofi India Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $9.0M Total Trade · DGFT Verified

Sanofi India Limited is an Indian pharmaceutical exporter with a total trade value of $9.0M across 4 products in 4 therapeutic categories. Based on 187 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ramipril ($4.5M), Codeine ($3.8M), Insulin ($640.4K).

Sanofi India Limited — Export Portfolio & Destination Treemap

Sanofi India Limited pharmaceutical export portfolio — 4 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Sanofi India Limited? — Company Overview & Market Position

Sanofi India Limited, established in 1956 as Hoechst Fedco Pharma Private Limited, is a leading pharmaceutical company headquartered in Mumbai, India. Over the decades, it has undergone several name changes, including Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited, and Aventis Pharma Limited, before adopting its current name in May 2012. The company is a subsidiary of Hoechst GmbH, which, along with Sanofi, holds a combined 60.4% stake in Sanofi India Limited.

Sanofi India Limited operates in the pharmaceutical sector, focusing on the manufacturing and trading of drugs and pharmaceutical products. The company employs approximately 1,225 individuals and offers a diverse portfolio of products across various therapeutic areas, including diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, central nervous system disorders, allergy, pain care, digestive, and nutritional health. Its product range includes well-known brands such as Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil.

What Does Sanofi India Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ramipril$4.5M

Product Portfolio — Top 4 by Export Value

Sanofi India Limited exports 4 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ramipril	Cardiovascular	$4.5M	90	5.0%	4
2	Codeine	Analgesics & Antipyretics	$3.8M	75	3.4%	4
3	Insulin	Diabetes & Endocrine	$640.4K	16	0.8%	10
4	Teicoplanin	Advanced Antibiotics	$101.2K	6	1.6%	7

Sanofi India Limited exports 4 pharmaceutical products across 4 therapeutic categories with a total export value of $9.0M. The top category is Cardiovascular (50.0% of portfolio), followed by Analgesics & Antipyretics (41.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Sanofi India Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Sanofi India Limited operates a state-of-the-art manufacturing facility in Goa, India. This site is designed to meet international Good Manufacturing Practice (GMP) requirements and has received approvals from major international regulatory agencies, including the German FDA, the European Economic Area (EAEU), and the Therapeutic Goods Administration (TGA) of Australia. The Goa facility is capable of producing up to 5 billion tablets and capsules annually, serving both domestic and export markets.

3Key Leadership

As of March 2026, the key leadership team at Sanofi India Limited includes:

Deepak Arora: Managing Director and General Manager of Pharma.

Rachid Ayari: Chief Financial Officer and Whole-Time Director.

Haresh Vala: Company Secretary and Compliance Officer.

Bratin Bag: Senior Director of Ethics and Business Integrity, South Asia.

Mahadev Gawade: Additional Whole-Time Director and Site Director - Goa.

These leaders play pivotal roles in steering the company's strategic direction and ensuring compliance with regulatory standards.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Sanofi India Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Sanofi India Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Goa has received approvals from the German FDA, EAEU, and TGA, indicating compliance with stringent international standards. This facilitates the export of its products to these regions. Additionally, Sanofi India's products are marketed under various brands, such as Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil, through independent distributors.

2Emerging Markets

Sanofi India Limited has expanded its reach to emerging markets, including Africa, Latin America, and Southeast Asia. The company's adherence to international GMP standards and its manufacturing facility's approvals from agencies like the German FDA, EAEU, and TGA enhance its ability to access these markets. While specific details on WHO prequalification are not provided, the company's compliance with international standards positions it favorably for entry into these regions.

3Geographic Strategy

Sanofi India Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Sanofi India Limited's manufacturing facility in Goa has received approvals from the German FDA, EAEU, and TGA, indicating compliance with international standards. While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, the facility's international approvals suggest a strong standing in regulatory compliance.

2WHO & EU GMP

Sanofi India Limited's manufacturing facility in Goa is designed to meet international GMP requirements and has received approvals from major international regulatory agencies, including the German FDA, EAEU, and TGA. While specific details regarding WHO prequalification and EU GMP certificates are not provided, the facility's adherence to international standards positions the company favorably in global markets.

3CDSCO & Indian Regulatory

Sanofi India Limited operates under the regulatory oversight of the Central Drugs Standard Control Organization (CDSCO) in India. The company's manufacturing facility in Goa is approved by major international regulatory agencies, including the German FDA, EAEU, and TGA, indicating compliance with stringent international standards. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed.

Sanofi India Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Sanofi India Limited operates in a competitive pharmaceutical market, facing competition from both multinational and domestic companies. Key competitors include Aurobindo Pharma Ltd, Torrent Pharmaceuticals Ltd, Strides Pharma Science Ltd, and GlaxoSmithKline Pharmaceuticals Ltd. While specific market share comparisons are not provided, Sanofi India's diverse product portfolio and adherence to international standards position it as a significant player in the Indian pharmaceutical industry.

2Key Differentiators

Sanofi India Limited's key differentiators include its extensive experience in the Indian pharmaceutical market, a diverse product portfolio across various therapeutic areas, and manufacturing facilities that adhere to international GMP standards. The Goa facility's approvals from major international regulatory agencies, such as the German FDA, EAEU, and TGA, further enhance the company's competitive advantage.

3Strategic Position

Sanofi India Limited's strategic direction focuses on delivering innovative healthcare solutions in preventive care, such as vaccines, and therapies for chronic conditions like diabetes and rare diseases. The company's adherence to international GMP standards and its manufacturing facility's approvals from agencies like the German FDA, EAEU, and TGA support its global expansion efforts. While specific details on future strategic initiatives are not publicly disclosed, the company's commitment to quality and innovation positions it well for sustained growth.

Buyer Due Diligence Brief — Evaluating Sanofi India Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Sanofi India Limited demonstrates a strong track record in manufacturing and exporting pharmaceutical products. The company's manufacturing facility in Goa is approved by major international regulatory agencies, including the German FDA, EAEU, and TGA, indicating a high level of reliability and compliance. Specific details regarding export volume and consistency are not publicly disclosed, but the company's adherence to international standards suggests a reliable supply chain.

2Certifications to Verify

Importers should verify the following certifications when considering Sanofi India Limited as a supplier:

FDA Approval: Confirm that the manufacturing facility is registered with the U.S. Food and Drug Administration (FDA).

WHO-GMP Certification: Ensure the facility adheres to World Health Organization Good Manufacturing Practice (GMP) standards.

EU GMP Certification: Verify compliance with European Union GMP standards.

Frequently Asked Questions — Sanofi India Limited

How many pharmaceutical products does Sanofi India Limited export from India?

Sanofi India Limited exports 4 pharmaceutical products across 4 therapeutic categories. The top exports are Ramipril ($4.5M), Codeine ($3.8M), Insulin ($640.4K), Teicoplanin ($101.2K). Total export value is $9.0M.

What is Sanofi India Limited's total pharmaceutical export value?

Sanofi India Limited's total pharmaceutical export value is $9.0M, based on 187 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Sanofi India Limited cover?

Sanofi India Limited exports across 4 therapeutic categories. The largest are Cardiovascular (50.0%, 1 products), Analgesics & Antipyretics (41.7%, 1 products), Diabetes & Endocrine (7.1%, 1 products).

Get Full Sanofi India Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.